Showing 2791-2800 of 4063 results for "".
- 2019 American Academy of Optometry Resident Travel Fellowship Recipients Announcedhttps://modernod.com/news/2019-american-academy-of-optometry-resident-travel-fellowship-recipients-announced/2476868/The American Academy of Optometry named the recipients of the 2019 Resident Travel Fellowship Awards. These travel fellowships will allow residents to attend Academy 2019 Orlando and 3rd World Congress of Optometry, October 23-27, 2019. Allergan Resident
- American Academy of Optometry Foundation Announces 2019 Fredric Rosemore Low Vision Educational Grant Recipienthttps://modernod.com/news/american-academy-of-optometry-foundation-announces-2019-fredric-rosemore-low-vision-educational-grant-recipient/2476860/The American Academy of Optometry Foundation (AAOF), in collaboration with the Fredric and Marion Rosemore Family Foundation, has announced that So-Yeon Sharon Lee, OD, FAAO, Dipl-ABO, was named the 2019 recipient of the Fredric Rosemore Low Vision Educational Grant. Dr. Lee is an Assistan
- iSTAR Medical Announces EUR 40 Million Series C Financinghttps://modernod.com/news/istar-medical-announces-eur-40-million-series-c-financing/2479542/iSTAR Medical announced the completion of a €40m Series C financing to support the development of iSTAR Medical’s MINIject device along the path to commercialization in Europe and the United States. MINIject, an ab-interno MIGS device, provides a powerful and reliable sol
- Hoya Vision Care Plans $25 Million Dollar Expansion of U.S. Labhttps://modernod.com/news/hoya-vision-care-plans-25-million-dollar-expansion-of-u-s-lab/2476833/Hoya Vision Care announced plans to invest more than $25 million in its Ramsey, Minnesota facility, according to a report in VisionMonday. The investment in facility
- Oxurion Reports Topline Month 3 Results of Phase 2a Study Evaluating THR-317 in Combination with Ranibizumab for DMEhttps://modernod.com/news/oxurion-reports-topline-month-3-results-of-phase-2a-study-evaluating-thr-317-in-combination-with-ranibizumab-for-dme/2479545/Oxurion NV reported topline data from a phase 2a study evaluating THR-317, a humanized antibody against placental growth factor (PlGF), in combination with anti-VEGF (ranibizumab), an anti-vascular endothelial growth factor (VEGF) antibody, for the treatment of diabetic macular edema (DME). <
- Regenxbio Reports Additional Positive Interim Phase 1/2a Trial Update for RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-reports-additional-positive-interim-phase-1-2a-trial-update-for-rgx-314-for-the-treatment-of-wet-amd/2476800/As part of its quarterly results reporting, Regenxbio provided an update on its phase 1/2a for RGX-314 for the treatment of wet AMD. “We are encouraged by the continued positive interim data from the phase 1/2a RGX-314 trial and the potential of NAV gene therapy as a one-time treatm
- Opthea Meets Primary Endpoint in Phase 2b Study of OPT-302 in Wet AMDhttps://modernod.com/news/opthea-meets-primary-endpoint-in-phase-2b-study-of-opt-302-in-wet-amd/2476795/Opthea announced positive phase 2b results demonstrating that OPT-302 combination therapy met the primary endpoint of superiority in mean visual acuity gain at 24 weeks compared to Lucentis monotherapy in treatment-naïve patients with wet age-related macular degeneration (AMD). <
- TopiVert Announces Topline Results from Phase 2b/3 Study of Dry Eye Disease Drug Candidatehttps://modernod.com/news/topivert-announces-topline-results-from-theia-1-phase-2b-3-clinical-study-of-top1630-as-a-treatment-for-dry-eye-disease/2476792/TopiVert Pharma announced topline results from THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1, a multicenter, randomized, double-masked, placebo-controlled phase 2b/3
- Alkahest Phase 2a Study AKST4290-202 in Refractory Wet AMD Meets Primary and Secondary Endpointshttps://modernod.com/news/alkahest-phase-2a-study-akst4290-202-in-refractory-wet-amd-meets-primary-and-secondary-endpoints/2476778/Alkahest announced that its phase 2a trial of AKST4290, an orally-administered small molecule CCR3 inhibitor, met the primary endpoint of achieving an increase in best corrected visual acuity (BCVA) in patients with refractory wet or neovascular age-related macular degeneration (nAMD). AKST4290 w
- B+L Introduces FreeFlow Infusion System and 23-Gauge Bi-Blade Dual Port Vitrectomy Cutterhttps://modernod.com/news/bausch-lomb-introduces-freeflow-infusion-system-for-retina-surgery/2476761/Bausch + Lomb announced the launch of the FreeFlow infusion system for retina surgery and the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The FreeFlow infusion system allows for higher level of infusion flow compared to previous generati